Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

  • Revenue in EUR (TTM)6.59bn
  • Net income in EUR59.31m
  • Incorporated1987
  • Employees23.74k
  • Location
    Grifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
  • Phone+34 935710000
  • Fax+34 935710267
  • Websitehttps://www.grifols.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BB BIOTECH AG692.85k-212.39m2.59bn----1.08--3,744.02-3.76-3.760.012242.360.0002-------7.262.34-8.252.52-760.8399.06-30,653.8635.40---0.23850.116217.78-57.97-37.9842.26-----8.09
Indivior PLC1.01bn1.85m2.69bn1.05k1,225.31--111.812.66-0.0376-0.03766.010.000.58721.454.61823,930.600.10741.320.28592.6282.9883.690.1832.680.859--1.000.0021.311.6996.00--5.27--
Virbac SA1.21bn119.46m2.93bn5.40k24.503.2517.672.4214.1214.12143.10106.420.87941.307.09224,710.408.597.2611.7010.3965.1965.809.768.981.25--0.15596.3414.317.137.78--6.98--
ALK-Abello A/S646.79m65.16m3.37bn2.82k59.316.1732.355.212.092.0920.9020.100.74021.326.111,708,215.007.463.509.424.3762.9160.6610.075.071.1835.050.14680.006.9410.6045.07--16.32--
Dottikon ES Holding AG347.69m88.58m3.42bn694.0038.153.9031.079.856.246.2424.4961.100.31350.63395.39498,861.307.997.489.588.4867.5878.9425.4822.351.65101.250.1062--26.8015.0947.9427.7030.78--
Krka d.d. Novo Mesto1.81bn313.95m4.21bn11.78k12.671.849.952.3310.1410.1458.3670.020.66271.353.96153,343.9011.5112.6413.7515.1256.8457.2917.3718.712.5419.990.0055--5.186.28-13.5812.458.35--
Siegfried Holding AG1.31bn115.19m4.27bn3.93k35.054.6621.423.2726.2826.28298.23197.490.69582.273.14323,288.606.176.517.677.9825.2023.248.869.061.397.930.346815.263.419.87-28.1618.3417.956.72
Laboratorios Farmaceuticos ROVI SA829.51m170.34m4.37bn2.11k25.257.7722.845.273.203.2015.5810.410.98831.045.13392,946.0020.2918.9028.8825.5859.3559.8220.5320.130.8575--0.107533.601.4422.30-14.6956.9315.8469.11
Richter Gedeon Vegyeszeti Gyar Nyrt2.04bn403.29m4.38bn12.17k10.791.508.162.14857.81857.794,349.056,173.080.59311.714.08--11.8311.6413.3913.2864.7558.1819.9518.933.127.490.015939.700.299312.57-6.0535.0615.5933.38
Orion Oyj1.19bn216.80m4.88bn3.63k22.345.4518.494.101.551.558.496.340.80881.575.56327,588.1014.7219.4718.0324.1655.3059.3818.2020.711.7594.790.183591.83-11.264.01-37.971.8911.821.55
Hikma Pharmaceuticals Plc2.67bn176.13m4.98bn8.97k28.322.4411.911.870.67740.677410.247.880.62841.763.67254,017.604.208.195.7211.3048.9450.296.6813.770.90297.680.350336.7114.226.731.06-7.597.974.54
DiaSorin SpA-100.00bn-100.00bn5.01bn3.28k--------------------------13.14--14.79--67.40--23.33------23.899.9816.38-22.5311.4921.765.29
Grifols SA6.59bn59.31m5.13bn23.74k92.510.97178.240.77830.09010.09019.808.580.30681.239.86277,627.000.84082.391.063.0437.8440.262.747.541.291.560.5593--8.718.00-71.52-36.98-0.8127--
Zealand Pharma A/S45.96m-94.36m5.72bn253.00--24.98--124.49-12.57-12.576.0127.280.19484.16289.881,354,889.00-39.99-42.74-46.30-50.2487.3996.13-205.30-464.666.23--0.0696--229.6555.2727.12--42.53--
BACHEM HOLDING AG593.46m114.99m6.66bn2.01k57.634.9141.2611.221.501.507.7317.610.37651.233.33287,794.607.298.858.1710.2830.6531.6319.3819.743.0429.800.000355.378.5715.3711.1019.1250.887.78
Data as of Mar 28 2024. Currency figures normalised to Grifols SA's reporting currency: Euro EUR

Institutional shareholders

16.23%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 29 Feb 202411.49m2.70%
Norges Bank Investment Managementas of 31 Dec 20239.59m2.25%
BNP Paribas Asset Management Europe SASas of 13 Mar 20248.38m1.97%
Capital Research & Management Co. (World Investors)as of 15 Mar 20248.09m1.90%
BlackRock Fund Advisorsas of 07 Mar 20246.97m1.64%
Hardman Johnston Global Advisors LLCas of 29 Dec 20236.42m1.51%
DWS Investment GmbHas of 31 Jan 20245.81m1.36%
Caixabank Asset Management SGIIC SAas of 31 Dec 20235.32m1.25%
Bestinver Gesti�n SA SGIICas of 31 Dec 20233.75m0.88%
Capital International Ltd.as of 07 Mar 20243.33m0.78%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.